Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Krebs, M. G., Cho, B. C., Hiret, S., Han, J.-Y., Lee, K. H., Llácer Pérez, C., De Braud, F., Haura, E. B., Sanborn, R. E., Yang, J. C.-H., Shu, C. A., Goto, K., Nishio, M., Zhao, J., Wang, Z., Tomasini, P., Felip, E., Goldman, J. W., Ou, S.-H. I., … Leighl, N. B. (2025). Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2025.05.012
Authors:
Matthew G Krebs
Byoung Chul Cho
Sandrine Hiret
Ji-Youn Han
Ki Hyeong Lee
Casilda Llácer Pérez
Filippo De Braud
Eric B Haura
Rachel E Sanborn
James Chih-Hsin Yang
Catherine A Shu
Koichi Goto
Makoto Nishio
Jun Zhao
Zhijie Wang
Pascale Tomasini
Enriqueta Felip
Jonathan W Goldman
Sai-Hong Ignatius Ou
Michael Boyer
Grace Gao
Siyang Qu
Joshua C Curtin
Xuesong Lyu
Robert W Schnepp
Priya Kim
Meena Thayu
Roland E Knoblauch
Patricia Lorenzini
Mahadi Baig
Alexander I Spira
Natasha B Leighl
Affiliated Authors:
Catherine A Shu
Columbia Affiliation:
Author Keywords:
chrysalis
met exon 14 skipping mutation
advanced non-small cell lung cancer
amivantamab
prior met therapies
elink
Publication Type:
Article
Unique ID:
10.1016/j.jtho.2025.05.012
PMID:
40383434
DOI:
10.1016/j.jtho.2025.05.012
Journal:
Journal of Thoracic Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: